G1 Therapeutics. has filed a patent for improved compounds and methods to protect healthy cells, including hematopoietic stem cells, from damage caused by chemotherapy. The invention involves selective CDK4/6 inhibitors for treating triple negative breast cancer. GlobalData’s report on G1 Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights G1 Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on G1 Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. G1 Therapeutics's grant share as of January 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

Method of treating triple negative breast cancer with cdk4/6 inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: G1 Therapeutics Inc

A recently filed patent (Publication Number: US20230381189A1) discloses a method for treating triple negative breast cancer (TNBC) in humans by administering a selective CDK4/6 inhibitor. The method involves administering an effective amount of the inhibitor to the patient. Additionally, the patent claims specify various chemotherapeutic agents that can be used in conjunction with the CDK4/6 inhibitor, including carboplatin, cisplatin, paclitaxel, doxorubicin, cyclophosphamide, and gemcitabine.

Furthermore, the patent also outlines a method for reducing chemotherapy-induced myelosuppression in humans undergoing chemotherapy for bladder cancer. This method involves administering an effective amount of at least one DNA damaging chemotherapeutic agent along with a CDK4/6 inhibitor. The patent specifies the timing of administration of the CDK4/6 inhibitor in relation to the DNA damaging chemotherapeutic agent, as well as the dosing schedule for the chemotherapeutic agent. Various DNA damaging chemotherapeutic agents are listed in the claims, including cisplatin, carboplatin, campothecin, doxorubicin, gemcitabine, and etoposide.

To know more about GlobalData’s detailed insights on G1 Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies